<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397733</url>
  </required_header>
  <id_info>
    <org_study_id>PREMER-TRIAL</org_study_id>
    <nct_id>NCT02397733</nct_id>
    <nct_alias>NCT02357875</nct_alias>
  </id_info>
  <brief_title>Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)</brief_title>
  <official_title>Phase III Trial Evaluating Memory Preservation of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in Small Cell LUNG Cancer (PREMER-TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigación Clínica en Oncología Radioterapia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study i sto evaluate the impact of prophylactic cranial&#xD;
      irradiation (PCI) with hippocampal avoidance in the neurocognitive function and quality of&#xD;
      life of small cell lung cancer patients.&#xD;
&#xD;
      In addition, the trial assesses the potential changes in hippocampal volumetry due to cranial&#xD;
      irradiation using magnetic resonance imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prophylactic cranial irradiation (PCI) has become a standard of care for selected patients&#xD;
      with limited and extensive stage small cell lung cancer (SCLC) who have shown benefit after&#xD;
      chemotherapy with or without thoracic radiotherapy.&#xD;
&#xD;
      Because hippocampal involvement by metastatic disease is rare, and because preclinical and&#xD;
      clinical evidence suggests that radiation dose received by the hippocampus during whole brain&#xD;
      radiotherapy may play a role in radiation-induced neurocognitive decline, sparing of the&#xD;
      hippocampus during the administration of PCI should result in lower rates of memory loss.&#xD;
&#xD;
      Previous studies have demonstrated the dosimetric capabilities of intensity modulated&#xD;
      radiation therapy (IMRT) to conformably avoid the hippocampus without detriment to the&#xD;
      radiation dose the remaining brain receives.&#xD;
&#xD;
      The main objective of this trial is compare neurocognitive functioning following hippocampal&#xD;
      avoidance PCI to standard PCI treatment measured by Free and Cued Selective Reminding Test&#xD;
      (FCSRT). The FCSRT measures verbal learning and memory. The FCSRT emphasizes encoding&#xD;
      specificity during learning and recall. One of the secondary objectives of this trial is to&#xD;
      test the hypothesis that the lowered neurocognitive function of the patients is due to a&#xD;
      substantial reduction in hippocampal volume in magnetic resonance imaging (MRI). Others&#xD;
      objectives are to evaluate quality of life (QoL) and the rate of metastases in the&#xD;
      hippocampus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive functioning (NCF) (Free and Cued Selective Reminding Test)</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Free and Cued Selective Reminding Test (FCSRT) evaluated at baseline and 3 months after radiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive functioning (NCF) (Free and Cued Selective Reminding Test)</measure>
    <time_frame>Change from baseline to 6,12 and 24 months</time_frame>
    <description>Free and Cued Selective Reminding Test (FCSRT) evaluated at baseline and 6,12 and 24 months after radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hippocampus brain metastases (brain magnetic resonance imaging) (MRI)</measure>
    <time_frame>Change from baseline to 3, 6,12 and 24 months</time_frame>
    <description>Evaluation of hippocampus brain metastases at 3, 6, 12 and 24 months after radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hippocampus volume (brain magnetic resonance imaging) (MRI)</measure>
    <time_frame>Change from baseline to 3, 6,12 and 24 months</time_frame>
    <description>Evaluation of hippocampus volume at 3, 6, 12 and 24 months after radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects (according to Common Toxicity Criteria for Adverse Effects)</measure>
    <time_frame>Change from baseline to 3, 6,12 and 24 months</time_frame>
    <description>Evaluation of adverse effects according to Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.0 at 3, 6, 12 and 24 months after radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (measured by European Organization for Research and Treatment of Cancer (EORTC) questionnaire (QLQ C-30 and QLQ BN-20)</measure>
    <time_frame>Change from baseline to 3, 6,12 and 24 months</time_frame>
    <description>Evaluation of Quality of Life (QoL) measured by European Organization for Research and Treatment of Cancer (EORTC) questionnaire (QLQ C-30 and QLQ BN-20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From the start date of PCI until the date of death from any cause, or the last follow-up date whichever came first, assessed up to 60months&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Prophylactic cranial irradiation (PCI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hippocampal avoidance PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic cranial irradiation (PCI)</intervention_name>
    <description>Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week</description>
    <arm_group_label>Prophylactic cranial irradiation (PCI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hippocampal avoidance PCI</intervention_name>
    <description>Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week</description>
    <arm_group_label>Hippocampal avoidance PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New diagnosed cytological or histologically confirmed Small cell lung carcinoma (stage&#xD;
             I-IV) candidate for PCI, for example, without progressive disease after&#xD;
             chemo-radiotherapy in stage I-III or after response after chemotherapy in stage IV&#xD;
&#xD;
          -  Performance status ≤ 1&#xD;
&#xD;
          -  Negative MRI of the brain within one month before protocol entry&#xD;
&#xD;
          -  Patient must give written informed consent before registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy to the brain&#xD;
&#xD;
          -  History of brain metastases&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Núria Rodríguez de Dios, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>+34683375231</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Del Mar. Radiation Oncology Department</name>
      <address>
        <city>Barcelona</city>
        <zip>08009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo de Investigación Clínica en Oncología Radioterapia</investigator_affiliation>
    <investigator_full_name>Nuria Rodriguez de Dios</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

